Screener
Royalty Pharma RPRX Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on the most recent quarter.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's net debt / EBITDA?
- Royalty Pharma (RPRX) reported net debt / EBITDA of 5.2× in Q4 2024.
- How has Royalty Pharma's net debt / EBITDA changed year-over-year?
- Royalty Pharma's net debt / EBITDA increased by 36.4% year-over-year, from 3.8× to 5.2×.
- What is the long-term trend for Royalty Pharma's net debt / EBITDA?
- Over 3 years (2020 to 2024), Royalty Pharma's net debt / EBITDA has grown at a 20.3% compound annual growth rate (CAGR), from 3× to 5.2×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Royalty Pharma's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude